Osal Fentanyl St Preferred2
For the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain SEPTEMBER 2014 VOLUME 12 ISSUE 3 The decision to use a specific opioid preparation should be based on (in particular) the patient’s preference for an individual preparation1 Association of Palliative Medicine pain news In a survey of user opinions of transmucosal fentanyl a publication of the british pain society product placebos, Abstral was rated most preferred2 It was easier to access, easier to administer and more palatable than the other placebos. 18 responders 6 responders 2 responders Abstral® placebo Effentora® placebo Instanyl® placebo This was a relatively small survey (n=30) and was not blinded, however the results provided valuable information about the practical preferences of patients with cancer pain for transmucosal fentanyl products.2 ® Because time is precious PRESCRIBING INFORMATION. Please refer to the full Summary of Product Characteristics before kidney dysfunction. Possible symptoms of withdrawal on cessation are anxiety, tremor, sweating, prescribing. paleness, nausea and vomiting. The development of a potentially life-threatening serotonin Name: Abstral 100 micrograms, Abstral 200 micrograms, Abstral 300 micrograms, Abstral syndrome may occur with the concomitant use of serotonergic drugs. Serotonin syndrome may 400 micrograms, Abstral 600 micrograms, Abstral 800 micrograms sublingual tablets. Active include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or Ingredient: Each tablet contains 100µg, 200µg, 300µg, 400µg, 600µg or 800µg fentanyl (as gastrointestinal symptoms. Discontinue Abstral if serotonin syndrome is suspected. Interactions: citrate). Indication: Management of breakthrough pain in adult patients using opioid therapy for Fentanyl is metabolised by CYP3A4. Use with caution if given concomitantly with CYP3A4 inhibitors chronic cancer pain.
[Show full text]